The American Cancer Society has introduced the American Cancer Society Center for Diversity in Cancer Research Training to address the lack of diversity in research environments. The new center will enhance the traditional academic journey, focusing on meeting potential researchers where they are and helping them overcome barriers to future success.
The American Cancer Society has introduced the American Cancer Society Center for Diversity in Cancer Research Training to address the lack of diversity in research environments.
The Cancer Society recently announced the new center will enhance the traditional academic journey, focusing on meeting potential researchers where they are and helping them overcome barriers to future success.
Initial programming will support underrepresented high school, college and post-baccalaureate students and include exposure to oncology and cancer research as a career. Mentorship, hands-on research experiences and career development will also be included.
The aim is to increase efforts to recruit and nurture individuals from diverse backgrounds within scientific and clinical training environments, according to a release by the Cancer Society.
"The center is a perfect way to build upon the Diversity in Cancer Research internship program we launched in 2021," said Dr. Ellie Daniels, MPH, senior vice president of the center," in the release. "Its success caused us to think about the support we could provide more broadly. Inequities impact cancer outcomes in tangible and intangible ways. Working to remove the academic barriers people of color face allows us to grow a pipeline of well-qualified researchers who have a unique connection to the communities we need to impact."
Today, the racial and ethnic communities that bear a disproportionate burden of cancer unfortunately continue to be underrepresented in the cancer research workforce. For example, while the number of biomedical scientists in the U.S. has grown since the 1990s, the percentage of African Americans and Hispanics in biomedical careers is lowest among any ethnic group, the release said.
In addition, funding rates for the National Institute of Health's R01 grant program, which serves as a catalyzing milestone in the academic careers of many research scientists, remains lowest for African American applicants at 16.6% compared to 27.8% for White applicants.
Lastly, people of color represent 20% of first-year college students pursuing degrees in science and engineering. The numbers decrease as these students move through their education with 17% receiving a bachelor's degree and only 10% completing advanced degrees in these disciplines.
Dr. Karen E. Knudsen, CEO of the American Cancer Society said the new initiative will help further enhance diversity in cancer research and cancer care and "expand the expert breadth of voices and innovative strategies to accelerate progress against cancer."
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More